FAP and melanoma: The results obtained in C57BL/6J syngeneic mouse models demonstrated that the highest antitumor efficacy against melanoma B16 was observed in DCs transduced with a vector containing a shRNA site against A20, tumor-associated antigen tyrosinase related protein-2 (TRP2), and FAPα-antigen for targeting CAF.